XBiotech Inc. (XBIT)
NMS · Healthcare · Biotechnology
$2.25
-0.88%
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
Market Cap
$68.6M
Shares Outstanding
30.5M
Exchange
NMS
Currency
USD
About XBiotech Inc.
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -6.3M | -6.0M | -29.8M | -6.3M |
| Net Income | -1.8M | -6.0M | -26.9M | -5.5M |
| Diluted EPS | $-0.06 | $-0.20 | $nan | $-0.18 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 4.0M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.4M | 0.00 | ||
| Operating Income | -34.5M | -37.5M | -42.5M | -55.7M |
| Net Income | -32.9M | -24.6M | -38.5M | -45.5M |
| Diluted EPS | $-1.08 | $-0.81 | $-1.26 | $-1.49 |